T-Rex 2X Long MSTR Daily Target ETF (MSTU) Stock Price Today
Aura AI Summary
Key Stats
- $855.73MMarket Cap
- 3,730,095Volume
- Leveraged / InverseSector
- $480.0052W High
- $14.6052W Low
- 18 DaysTypical Hold Time
- -Enterprise Value
- -Div Yield
- 60% Sell | 40% BuyTrading Activity
Track T-Rex 2X Long MSTR Daily Target ETF (MSTU) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, T-Rex 2X Long MSTR Daily Target ETF has traded between a low of $14.6 and a high of $480, highlighting its annual price range. Buy and sell T-Rex 2X Long MSTR Daily Target ETF shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About T-Rex 2X Long MSTR Daily Target ETF
MSTU is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bullish (long) position in MSTR, a company known for its significant Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Most Recent News
Helium readings hit record highs at HeLIX's Montana Ollie well, advancing towards flow testing and production.
HeLIX Exploration's Ollie #1 well at the Rudyard project in Montana reached a depth of 6,311 ft ahead of schedule and under budget, recording the highest helium mudlog readings in the field at 4,800 ppm. This significant increase from the previous 1,...

Zinc, lead, and copper production rise sharply at Central Asia Metals, keeping full-year targets on track.
Central Asia Metals reported strong third-quarter production increases at its Sasa mine, with zinc output up 18% and lead up 21%, driven by higher ore grades. Copper production at the Kounrad mine in Kazakhstan also advanced, supporting the company's...

Futura Medical plans 2027 launch of improved Eroxon Intense gel after strong user test results
Futura Medical reported positive results from a home user test of its erectile dysfunction gel, Eroxon Intense, involving 115 men aged 18-59. The test showed a 7.86-point improvement on the erectile function scale, surpassing previous results and cli...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.